Document:

EX-10.2

 Exhibit 10.2 
  

 
 August 5, 2015 
 Robert
Bazemore 
 c/o Epizyme, Inc. 
 400 Technology Square 

Cambridge, MA 02139 
 Dear Rob: 

It is my pleasure to extend to you this offer of employment with Epizyme, Inc. (the “Company”). On behalf of the Company, I am pleased to set forth
below the terms of your employment with the Company: 
  

	 	1.	Employment. You will be employed to serve on a full-time basis as an employee of the Company, commencing on August 5, 2015 (the “Commencement Date”), and will be appointed President and
Chief Executive Officer effective September 10, 2015. As President and Chief Executive Officer, you will be responsible for such duties as are consistent with such position, plus such other duties as may from time to time be assigned to you by
the Company. You shall report to the Board of Directors of the Company (the “Board”), and you agree to devote your full business time, best efforts, skill, knowledge, attention and energies to the advancement of the Company’s business
and interests and to the performance of your duties and responsibilities as an employee of the Company. You agree to abide by the rules, regulations, instructions, personnel practices and policies of the Company and any changes therein that may be
adopted from time to time by the Company. 

  

	 	2.	Base Salary. Your base salary will be at the rate of $21,875 per semi-monthly pay period (which if annualized equals $525,000), less all applicable taxes and withholdings, to be paid in installments in
accordance with the Company’s regular payroll practices. Such base salary may be adjusted from time to time in accordance with normal business practices and in the sole discretion of the Company. 

 

	 	3.	Discretionary Bonus. Following the end of each fiscal year and subject to the approval of the Board, you may be eligible for a retention and performance bonus, based on your performance and the
Company’s performance during the applicable fiscal year, as determined by the Company in its sole discretion. The bonus payable to you for 2015, if any, will be prorated to reflect the portion of 2015 for which you served as President and Chief
Executive Officer of the Company. Your target bonus is 50% of your annualized base salary. Such target bonus may be adjusted from time to time in accordance with normal business practices and in the sole discretion of the Company. You must be an
active employee of the Company on the date any bonus is distributed in order to be eligible for and to earn a bonus award, as it also serves as an incentive to remain employed by the Company. 

	 	4.	Equity. Subject to Board approval, you will receive a stock option grant under the Company’s 2013 Stock Incentive Plan (the “Plan”) for the purchase of 300,000 shares of common stock of the
Company at an exercise price per share equal to the fair market value of one share of Common Stock on the date of the grant as determined by the Company in its sole discretion. The stock option grant shall be subject to all terms and other
provisions set forth in the Plan and in a separate stock option agreement, including the vesting schedule. The option will vest over a four-year period with the first quarter vesting on the first anniversary of the Commencement Date and the
remaining three-fourths vesting monthly in 36 equal monthly installments following the first anniversary of the Commencement Date and until fully vested on the fourth anniversary of the Commencement Date, subject to your continued employment with
the Company through each vesting date. 

 You may also be eligible for other grants of stock or stock options as determined by
and in the sole discretion of the Board. Nothing in this section shall affect your status as an employee at will, as set for below. 
  

	 	5.	Benefits. You may participate in any and all benefit programs that the Company establishes and makes available to its employees from time to time, provided that you are eligible under (and subject to all
provisions of) the plan documents that govern those programs. Benefits are subject to change at any time in the Company’s sole discretion. 

  

	 	6.	Vacation. You will be eligible for a maximum of three (3) weeks of paid vacation per calendar year to be taken at such times as may be approved in advance by the Company. The number of vacation days
for which you are eligible shall accrue at the rate of 1.25 days per month that you are employed during such calendar year. Your accrual and use of vacation time will be pursuant to Company policy, as established and as may be modified in the sole
discretion of the Company from time to time. 

  

	 	7.	Invention, Non-Disclosure, Non-Competition and Non-Solicitation Obligations. In exchange for your employment with the Company pursuant to the terms and conditions herein, you hereby agree to execute and
adhere to the obligations set forth in the enclosed Employee Invention and Non-Disclosure Agreement, which is a condition to your employment with the Company. 

  

	 	8.	At-Will Employment. This letter shall not be construed as an agreement, either express or implied, to employ you for any stated term, and shall in no way alter the Company’s policy of employment
at-will, under which both the Company and you remain free to end the employment relationship for any reason, at any time, with or without cause or notice. Similarly, nothing in this letter shall be construed as an agreement, either express or
implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company, except as otherwise explicitly set forth herein. This letter supersedes all prior understandings, whether written or oral, relating to
the terms of your employment. 

  
 -2- 

	 	9.	Severance Benefits. In recognition of your position with and value to the Company, and to provide you with assurance in the event of certain employment terminations, you have been selected to participate
in the Company’s Executive Severance and Change in Control Plan, a copy of which is enclosed with this letter. 

 If this letter
correctly sets forth the terms under which you will be employed by the Company, please sign and return to me, no later than August 5, 2015, the enclosed duplicate of this letter and the Employee Invention and Non-Disclosure Agreement. 

 

									
		  		  		  	Sincerely,
					
		  		  		  	By:	  	 /s/ David Mott

		  		  		  		  	David Mott
		  		  		  		  	Director
	
	The foregoing correctly sets forth the terms of my at-will employment with Epizyme, Inc. I am not relying on any representations other than those set forth above.
					
	 /s/ Robert Bazemore
	  		  		  		  	 August 5, 2015

	Robert Bazemore	  		  		  		  	                Date

  
 -3-Exhibit 10.3

 

Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 240-24b-2

 

Change Order Form # 26

 

Change order under Agreement dated: Fifth Amendment to Development and Clinical Supplies Agreement dated December 14, 2012

 

Between:  Radius Health, Inc and 3M

 

Project Name: For the development of Radius’ Abaloparatide compound delivered via 3M’s Microstructured Transdermal Delivery System

 

Change requested by: Radius
 Name: Michele Gehrt
 Company: 3M

Date: 13May2015

 

Description of change:

 

Radius has requested that 3M continue to progress the redevelopment of the Abaloparatide sMTS product to achieve a PK profile comparable to Abaloparatide-SC, as evaluated in [*] . This change order will progress the work completed in Change Order #22.

 

Scope:

 

3M to produce supplies of the sMTS Abaloparatide product ([*]) to achieve a PK profile comparable to SC injection. Redevelopment to increase the amount of Abaloparatide released may include changes in [*].  3M to prepare [*] product configurations for evaluation in [*] studies.

 

Assumptions:

 

·                3M will progress several product configurations that will build on the knowledge from previous w,ork.

·                3M will evaluate the [*] product configurations via [*].

·                The JTT will agree upon the product configurations to be taken into each [*] study.

·                Supplies for [*] studies would be produced as for past preclinical studies (non-GLP, non­ sterile) and shipped to the facility of Radius’ designation.

·                 Stability for promising configurations would be characterized only grossly

 

DELIVERABLES

 

·                Samples (approx [*] patch assemblies) for promising configurations agreed to by the JTT for further evaluation by Radius in [*]. [*] product configurations will be provided for [*] studies.

·                Gross stability evaluations for promising patch assembly configurations (limited testing at up to [*] time points for [*] storage condition).

 

1

 

·                Analysis of residual content on dosed arrays will be conducted if agreed to by JTT as necessary for understanding outcomes of the studies.

 

TIMING

 

The required effort in hours, duration of the study in months, and expected end dates for the study covered by this work plan are summarized in the table below.

 

	
Task
    	
 
    	
Estimated
   Effort
   (hours)
    	
 
    	
Estimated
   Duration
   (months)
    	
 
    	
Estimated
   Direct Costs
   ($)
    	
 
    	
Estimated End
   Date*
    	
 
    
	
Reformulation Tasks; Assessment   of Release in [*]; Preparation of Samples for PK Evaluation in [*]
    	
 
    	
300
    	
 
    	
1
    	
 
    	
$
    	
2,500
    	
 
    	
31May2015
    	
 
    
											

 

*timing depends on duration and scheduling of [*] studies

 

Total Estimated Costs: $ 67,000

 

In all other respects, the terms and conditions of the Agreement remain in full force and effect.

 

	
Requested task, dates and costs   are approved by:
    	
 
    
	
 
    	
 
    
	
Company: Radius   Health, Inc
    	
Company: 3M
    
	
Name: Gary   Hattersley
    	
Name: Michele Gehrt
    
	
Signature:
    	
/s/   Gary Hattersley
    	
 
    	
Signature:
    	
/s/   Michele Gehrt
    
	
Position: CSO
    	
Position: Commercialization Mgr
    
	
Date (dd/mm/yy):   13 May 2015
    	
Date (dd/mm/yy): 13/05/15
    
					

 

2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00248-of-00352.parquet"}]]